Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)

…, P Kaur, G Jevalikar, HK Gill, NS Choudhary… - Diabetes …, 2018 - Am Diabetes Assoc
OBJECTIVE Sodium–glucose cotransporter 2 (SGLT-2) inhibitors have been shown to reduce
liver fat in rodent models. Data regarding the effect of SGLT-2 inhibitors on human liver fat …

[HTML][HTML] Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome …

AS Soin, K Kumar, NS Choudhary… - The Lancet …, 2021 - thelancet.com
Background Global randomised controlled trials of the anti-IL-6 receptor antibody tocilizumab
in patients admitted to hospital with COVID-19 have shown conflicting results but potential …

[HTML][HTML] Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)

MS Kuchay, S Krishan, SK Mishra, NS Choudhary… - Diabetologia, 2020 - Springer
Aims/hypothesis Liraglutide, a daily injectable glucagon-like peptide-1 receptor (GLP-1r)
agonist, has been shown to reduce liver fat content (LFC) in humans. Data regarding the effect …

Acute and chronic rejection after liver transplantation: what a clinician needs to know

NS Choudhary, S Saigal, RK Bansal, N Saraf… - Journal of clinical and …, 2017 - Elsevier
While antibody mediated hyper-acute vasculitic rejection is rare in liver transplant recipients,
acute and chronic rejection have clinical significance. The liver allograft behaves differently …

Pathophysiological mechanisms underlying MAFLD

MS Kuchay, NS Choudhary, SK Mishra - Diabetes & Metabolic Syndrome …, 2020 - Elsevier
Background and aims The pathophysiology underlying metabolic associated fatty liver
disease (MAFLD) involves a multitude of interlinked processes, including insulin resistance (IR) …

Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study

S Ghosh, NS Choudhary, AK Sharma… - Liver …, 2013 - Wiley Online Library
Background Various vasoconstrictors have shown promising results in the management of
type 1 hepatorenal syndrome ( HRS ). However, there are very few studies on vasopressors …

APACHE II score is superior to SOFA, CTP and MELD in predicting the short‐term mortality in patients with acute‐on‐chronic liver failure (ACLF)

A Duseja, NS Choudhary, S Gupta… - Journal of digestive …, 2013 - Wiley Online Library
Objective The aim of the study was to assess the performance of various prognostic scores
including the acute physiology and chronic health evaluation ( APACHE II ), sequential organ …

[HTML][HTML] Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD)

NS Choudhary, A Duseja - Translational gastroenterology and …, 2021 - ncbi.nlm.nih.gov
Inter-individual and inter-ethnic differences and difference in the severity and progression of
liver disease among patients with non-alcoholic fatty liver disease (NAFLD) and alcoholic …

Peroxisome proliferator-activated receptors and their agonists in nonalcoholic fatty liver disease

NS Choudhary, N Kumar, A Duseja - Journal of Clinical and Experimental …, 2019 - Elsevier
Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide.
In addition to the liver-related morbidity and mortality, NAFLD is now also associated with …

Non-hepatic insults are common acute precipitants in patients with acute on chronic liver failure (ACLF)

…, RK Dhiman, A Kumar, N Choudhary… - Digestive diseases and …, 2010 - Springer
Introduction Acute-on-chronic liver failure (ACLF) is a newly coined term to describe
simultaneous coexistence of two liver conditions, one of them being chronic or long-standing and …